Thromboelastometric evaluation of hemostasis in dogs infected with Leishmania infantum

(Article begins on next page)

15 October 2023

Thromboelastometric evaluation of hemostasis in dogs infected with Leishmania infantum

Abstract

Objective – Evaluation of hemostasis via thromboelastometry in dogs with leishmaniasis before and after treatment.

Design – Longitudinal observational study.

Setting – University Veterinary Teaching Hospital.

Animals – Eighty-four adult, client-owned dogs.

Measurements and Main Results –Whole blood samples for the coagulation profile were collected from symptomatic dogs with leishmaniasis (group S), asymptomatic dogs with leishmaniasis after treatment (group T), and a control group of healthy dogs (group H). Hemostasis was evaluated by means of standard coagulation profile (PT, aPTT and fibrinogen) and by thromboelastometry (ROTEM). PT and aPTT were within the upper reference range in all three groups. Comparison of the ROTEM variables between the three groups showed statistically significant differences between group S versus groups T and H, but remaining within the reference ranges. Statistically significant differences in hematocrit and fibrinogen concentrations were noted between groups (Group S vs. H: hematocrit $P=0.001$, fibrinogen $P=0.002$; Group S vs. T: hematocrit $P=0.001$, fibrinogen $P=0.001$). These variations have interfered with some parameters of the ROTEM profile.

Conclusions – This study showed normal standard coagulation profiles in all three groups. The ROTEM results did not fall outside of the maximum values of the reference ranges.

Key words: small animal, hemostasis, leishmaniasis, thromboelastometry.

aPTT activated partial thromboplastin time

CFT clot formation time

CT clotting time

27   Group H control group

28   Group S symptomatic dogs before treatment

29   Group T asymptomatic dogs after treatment

30   MCF maximum clot firmness

31   PT prothrombin time

32   TEG thromboelastography

33   TEM thromboelastometry

34

35

36   **Introduction**

37   Leishmaniasis is an infective zoonosis caused by a protozoan of the genus *Leishmania*. It is

38   endemic to the Mediterranean basin and the dog is the primary reservoir of infection. A chronic

39   disease with many and different clinical signs, canine leishmaniasis can stimulate the

40   overproduction of antibody-forming immune complexes.[1,2] Their subsequent deposition in different

41   tissues ensues in skin and ocular lesions, renal failure and vasculitis, and inflammatory cytokine

42   production. [3-7] Other clinical conditions known to be associated with leishmaniasis, such as

43   epistaxis, hematuria, thromboembolism and disseminated intravascular coagulation (DIC), are

44   related to alterations in primary and secondary hemostasis.[8-11]

45   Several studies have signaled thrombocytopenia and a decrease in platelet function in canine

46   leishmaniasis, [12-17] whereas investigation of secondary hemostasis and fibrinolysis has given

47   discordant results. Indeed, some studies reported hypocoagulability due to an increase in activated

48   partial thromboplastin time (aPTT), while others described compensated disseminated intravascular

49   coagulation (DIC) due to an increase in fibrinogen degradation product (FDP) with normal

50   fibrinogen levels. [13,14,18]

51   To the best of our knowledge, only three studies to date have evaluated the effects of treatment on

52   hemostasis in dogs with leishmaniasis. Valladares and others (1998) evaluated the effects of therapy

with meglumine antimoniate on platelet, prothrombin time (PT), aPTT, fibrinogen and FDP in experimentally infected beagles. Alterations shown before treatment were a decrease in platelet count and aggregation and an increase of FDP. After treatment, platelet function an number normalized, while FDP decreased but then returned to within the normal range. [13]

Cortese and others (2008) studied the effects of prednisone on standard coagulation profile (PT, APTT and fibrinogen) and platelet aggregation in dogs treated with meglumine antimoniate and allopurinol. The dogs showed a decrease in platelet aggregation before treatment. A significant improvement in platelet aggregation was detected after treatment but the values remained lower than in the control group at the end of the study.[19] A later study by Cortese (2009), assessed hemostasis before and after treatment in dogs with *Leishmania infantum* or *Ehrlichia canis* or both. The dogs with single infection (leishmaniosis or ehrlichiosis) showed a decrease in platelet number and function that improved after treatment but did return to normal. In the dogs with double infection, platelet aggregation after treatment was still significantly lower than that in the healthy dogs. [20]

Previous studies have assessed hemostasis by means technologies that evaluate single steps of coagulation; hemostasis, however, is a dynamic process that involves plasmatic factors and cells (cell-based model of coagulation). [21] Viscoelastic techniques are recent methods for evaluating hemostasis. They rely on the use of whole blood to obtain a description of coagulation which more likely reflects in vivo hemostatic processes. Recently, thromboelastometry/thromboelastography have been used to identify hypocoagulability and hypercoagulability in dogs. [22-26]

Thromboelastometry measures clot formation kinetics, clot firmness and rate of dissolution (fibrinolysis); the results of the analysis are presented graphically.[27,28] For each sample, ROTEM generates different profiles, including: the in-TEM profile for the intrinsic pathway; the ex-TEM profile for the extrinsic pathway; and the fib-TEM profile correlated to functional fibrinogen levels. Hemostasis is assessed using whole blood, taking into account both the plasma and cellular components.

The first aim of this study was to evaluate hemostasis by means of a standard coagulation profile and thromboelastometry (ROTEM) in dogs with untreated leishmaniasis. The second aim was to determine whether the hemostatic alterations regressed in treated dogs. Our hypothesis was that in symptomatic dogs the infection affects hemostasis and that the alterations regress after therapy.

MATERIALS AND METHODS

Animals

The study protocol was approved by the Bioethical and Animal Welfare Committee of our institution. The dog owners were informed about the study protocol and gave their written consent for participation in the study.

All dogs were patients admitted to the Veterinary Teaching Hospital because of suspected infection of *Leishmania infantum* based on clinical signs. Physical examination, complete blood count [a], and biochemical evaluation [b], serum protein electrophoresis, urinalysis [reactive strips [c] and sediment analysis], protein/creatinine ratio, serological tests for *Leishmania infantum* [immunofluorescence antibody test (IFAT) performed at the Istituto Zooprofilattico Sperimentale of Piemonte, Liguria and Valle d'Aosta laboratory], and serological tests for *Ehrlichia canis* [d], *Borrelia burgdorferi* [d], *Anaplasma phagocytophilum* [d] and *Dirofilaria immitis* [d] were performed. To establish the diagnosis of leishmaniasis, cytology and/or PCR of lymph node samples obtained by fine needle aspiration (PCR performed at the Istituto Zooprofilattico Sperimentale of Piemonte, Liguria and Valle d'Aosta laboratory) were carried out. Dogs positive for *Leishmania infantum* on the basis of cytology or PCR of lymph node aspirate were considered to be affected by leishmaniosis if they presented clinical signs and laboratory tests suggestive of infection (Table 1). These dogs were divided in two groups: group S (symptomatic dogs before treatment) included sick dogs with clinical signs of *Leishmania* (stage C according to the guidelines);[29] group T (asymptomatic dogs after treatment) included dogs treated with meglumine antimoniate and allopurinol or miltefosine and allopurinol [according to the guidelines (Table 2)][30] and had completed therapy at least 2

months prior to enrolment in this study, did not present clinical signs compatible with

leishmaniasis, and had an albumin/globulin ratio (A/G) > 0.6.

The control group (group H) included dogs admitted to the Veterinary Teaching Hospital for routine

hematological control before spaying/castration or blood donation. The dogs were deemed healthy

on the basis of complete history and physical examination, CBC and biochemical analysis,

coagulation profile and not exposed or infected by *Leishmania* (serological tests [d], IFAT, cytology

and/or PCR analysis of lymph node).

Exclusion criteria were a positive result for *Ehrlichia canis*, *Borrelia burgdorferi*, *Dirofilaria*

immitis and *Anaplasma phagocytophilum*, and the administration of non-steroidal anti-

inflammatory drugs, corticosteroid or transfusion during the 2 months prior to enrolment in the

study. At enrolment, prophylactic treatment for sand fly was recommended.

Hemostasis

Samples of whole blood for the coagulation profile were collected by jugular venipuncture (20-

gauge needle) and placed into two tubes containing 3.2% trisodium citrate (1 part citrate: 9 parts

blood) [e]. Samples that were difficult to obtain (e.g., repeated venipuncture attempts, needle

repositioning or interruption of blood flow into the tube) were discarded and blood draws were

made from the contralateral jugular vein.

Secondary hemostasis was evaluated by means of standard plasma based assays (PT, aPTT and

fibrinogen)[f]. For thromboelastrometry with the ROTEM [g], whole blood samples were stored at 37

°C in 3.2% trisodium citrate tubes and analyzed 30 minutes after collection according to the

manufacturer's instructions; the analyses were run for 60 minutes. For each sample, in-TEM, ex-

TEM and fib-TEM profiles were performed to evaluate the intrinsic pathway (with activation by

ellagic acid) [h], the extrinsic pathway (with tissue factor activation) [i], and fibrinogen function

(platelets inactivated with cytochalasin D) [l], respectively. The following parameters were assessed

for each profile: clotting time ([CT], s); clot formation time ([CFT], s); maximum clot firmness

131 ([MCF], mm); α angle (α, °); profiles are presented as reaction curves (Fig. 1). CT represents the

132 first phase of fibrin formation, from activation of the test to a clot amplitude of 2 mm; this

133 parameter is mainly affected by the concentration of plasma coagulation factors and coagulation

134 inhibitors (e.g., antithrombin or drugs).[26,27] CFT expresses the velocity of clot formation and is

135 affected predominantly by platelet count and function and by fibrinogen activity. MCF, the

136 maximum firmness the clot reaches, is determined by both platelet count and function and fibrin

137 formation in the presence of factor XIII.[26,27] The α angle corresponds to the slope of the tangent on

138 the elasticity curve; it describes the kinetics of clot formation and is affected predominantly by

139 platelet count and function and fibrinogen.[26,27]

140 Abnormal ROTEM tracings were defined as ROTEM results outside of the maximum or minimum

141 values of our reference ranges (Table 3), hypercoagulable tracings when there was a decrease in CT

142 and CFT and an increase in MCF, α angle or a combination thereof, and hypocoagulable tracings

143 when there was an increase in CT and CFT and a decrease in MCF, α angle or a combination

144 thereof.

145

146 **Statistical analysis**

147 The data were entered into an ad hoc database [n]. All coagulation variables are continuous values

148 and were checked for normality by means of a test for normality based on skewness and another test

149 based on kurtosis; the two tests were then combined into an overall test statistic.

150 To test the differences between the three groups (H, S, T), the continuous outcome variables were

151 analyzed with ANOVA if they resulted normally distributed and were compounded by the

152 Bonferroni correction to identify the ties of any differences, otherwise the Kruskall-Wallis test was

153 performed. The two sample Mann-Whitney test was used to identify where the differences lay, as

154 suggested by Altman (1991).[31] Variables such as age, platelet, fibrinogen, hematocrit,

155 protein/creatinine ratio and creatinine were also compared.

Forward stepwise linear regression analysis was applied to the logarithmic transformation of the variables to determine whether any single ROTEM parameter correlated with the blood variables and resulted significantly different in the three groups. The significance level for addition to the model was fixed; terms with P<0.2 were eligible for addition. Significance was set at P<0.05.

Results

One hundred dogs were enrolled in the study: 45 in group S, 34 in group T and 31 in group H. Sixteen dogs in group S were excluded (infected but without clinical signs of leishmaniasis [n=5], neoplasia [n=3], positive for *Dirofilaria immitis* [n=4], and positive for *Ehrlichia canis* [n=4]) and 10 in group T (neoplasia [n=2] and A/G ≤0.6 [n=8]). Twenty-nine dogs were included in group S (Figure 2): 19 males (15 intact and 4 neutered) and 10 females (4 entire and 6 spayed), age range 1-14 years (mean age 6.1 ± 3.5; body weight 20.4 ± 13.3 kg). Twenty-four dogs were included in group T (Figure 3): 15 males (12 intact and 3 neutered) and 9 females (6 intact and 3 spayed), age range 2-14 years (mean age 5.8 ± 3.5; body weight 18.3 ± 3.5 kg). Finally 31 dogs were included in group H (Figure 4): 16 males (15 intact and 1 neutered) and 15 females (8 intact and 7 spayed), age range 1-18 years (mean age 5.6 ± 3.7; body weight 23.5 ± 8 kg).

In group S 20/29 dogs (69%) were anemic [median 32.9%, min 20, max 42], 2/29 (7%) were thrombocytopenic [median $261x10^3$/µL ($261x10^9$/L), min 107, max 670], 2/29 (7%) had a creatinine level outside of the upper reference range [median 0.82 mg/dL (7.,5 µmol/L), min 0.47, max 3.5], none had transaminase levels outside of the reference range, 20/29 (69%) had proteinuria [median 0.88, min 0.034, max 9.1], none had PT or aPTT outside of the upper reference range, and 13/29 (45%) had fibrinogen levels outside of the upper reference range [median 424 mg/dL (12.5 µmol/L), min 180, max 1094]. In group T 4/24 (17%) dogs were anemic [median 43.3%, min 31.6, max 56.4], none were thrombocytopenic, had creatinine levels outside of the upper reference range, or transaminase levels outside of the reference range, 2/24 (8%) had proteinuria [median 0.17, min

181   0.02, max 4.54], none had PT or aPTT outside of the upper reference range, and 1/24 (4%) had

182   fibrinogen level outside of the upper reference range [median 273 mg/dL (8 μmol/L), min 150, max

183   926]. None of the dogs in group H presented alterations in CBC, biochemical profile, urinalysis,

184   protein/creatinine ratio, serum protein electrophoresis or standard coagulation profile.

185   There was no significant difference in the mean age between the three groups.

186   The ROTEM results and their comparison are represented as box plots in Figure 5. Comparison of

187   the thromboelastometric variables between groups S and H showed a significant decrease in CT on

188   the ex-TEM profile (P=0.0002) and a significant decrease in CFT on the in-TEM (P=0.0002) and

189   ex-TEM (P=0.00001) profiles for the symptomatic (group S) dogs; furthermore, there was an

190   increase in MCF (in-TEM P=0.0116; ex-TEM P=0.0146; fib-TEM P=0.00001) and α angle (in-

191   TEM P=0.0001; ex-TEM P=0.00001; fib-TEM P=0.001) on all profiles. Comparison of the

192   ROTEM values between group S and group T revealed a significant decrease in CFT on the in-

193   TEM (P=0.0064) and ex-TEM (P=0.00363) profiles and a significant increase in MCF on the in-

194   TEM (P=0.00352) and fib-TEM (P=0.0009) profiles for group S; furthermore, there was a

195   significant increase in α angle on the in-TEM (P=0.0179) and ex-TEM (P=0.0074) profiles. Finally,

196   comparison between groups T and H showed no significant differences, except for a significant

197   decrease in CT on the ex-TEM profile (P=0.0001) and a significant increase in MCF (P=0.00372)

198   and α angle (P=0.0259) on the fib-TEM profile for group T.

199   Variables such as age, creatinine, protein/creatinine ratio, platelet, hematocrit and fibrinogen were

200   compared. Some statistically significant differences emerged for hematocrit and fibrinogen

201   concentration (Table 4).

202   Table 5 reports the results of the forward stepwise linear regression; the data were adjusted for

203   group of belonging. Plasma fibrinogen concentration was significantly associated with all

204   parameters of the ex-TEM profile, with CFT, MCF and α angle of the in-TEM profile, and with CT

205   and MCF on the fib-TEM profile. The variations in hematocrit interfered with α angle on the ex-

TEM profile. Platelet concentration, though not significantly different in the three groups, was associated with MCF on both the ex-TEM and in-TEM profiles and with CFT on the in-TEM profile.

Discussion

This study evaluated hemostasis in dogs with *Leishmania infantum* and assessed whether the hemostatic differences regressed in the treated dogs.

Leishmaniasis is known to stimulate overproduction of antibodies, with nearly no cellular response, forming abundant circulating immune complexes that can deposit in various different tissue and cause inflammation and vasculitis. [3,32,33] A recent study compared severe visceral leishmaniasis with a systemic inflammatory response syndrome.[34] The cell-based model of coagulation allowed to identify a two-way interaction between hemostasis and inflammation; indeed, some prothrombotic activated factors, such as FXIIa, activate neutrophils and complement, stimulate monocytes and the release of inflammatory cytokines, and thrombin has a chemotactic action on neutrophils and macrophages.[35] The inflammation that attends the coagulation process alters the cell membrane (the surfaces develop a procoagulant activity), leading to the production of inflammatory cytokines, the expression of tissue factor and a decrease in the production of antithrombin and FXII in the acute phase.[36]

The standard coagulation profiles were normal in all three groups in our study. Previous studies reported normal PT and aPTT in Beagle dogs with experimentally induced leishmaniasis and in naturally infected dogs.[13,19,20] In contrast, an increase in aPTT was described in dogs with leishmaniasis that showed an increase in alanine aminotransferase, and prolongation of PT and aPTT was noted in a dog with DIC and nephrotic syndrome caused by leishmaniasis.[9,14,18] From these studies it follows that altered standard coagulation profiles were described in dogs with leishmaniasis and concomitant organ damage or dysfunction.

In contrast with previous studies reporting normal fibrinogen levels, we noted an increase in fibrinogen concentration in some group S dogs.[13,18-20] The body responds to injury and infectious agents with a complex series of events that activate the inflammatory response.[37] The increase in fibrinogen could reflect the inflammatory state related to this disease, and the discrepant results obtained in these studies might be due to differences in the populations investigated.

The ROTEM results in the group S dogs showed some statistically significant differences as compared to those of the groups T and H but none of the results fell outside of the maximum values of the reference ranges.

The dogs in group S showed abnormalities on blood and urine testing typical of dogs with leishmaniasis. Alterations of some hematological or biochemical parameters are known to influence the results of ROTEM/thromboelastography (TEG) analysis. [38]

A recent study found a correlation between haematocrit, platelet count, plasma coagulation factors and ROTEM results in canine whole blood samples.[38] Smith et al. (2012) reported that hematocrit was correlated with all parameters on the in-TEM and ex-TEM profiles, except for CT on the in-TEM profile.[38,39] Decreased hematocrit, despite the presence of red cell mass within the reference ranges, can cause a relatively hypercoagulable trend of ROTEM variables. Furthermore, some studies reported a correlation between platelet concentration and CFT, α angle and MCF on in-TEM and ex-TEM profiles, as well as a significant association between the thromboelastographic (TEG) values of global clot strength (G) and platelet count.[38,40] Additionalle, these studies showed that a reduction in platelet count corresponds to a hypocoagulable tendency in ROTEM and TEG variables. [38,40] In contrast, a recent study reported a relative hypercoagulable trend in thrombocytopenic dogs with uncomplicated babesiosis.[41]

Also, plasma fibrinogen concentration has been significantly correlated with CFT, α angle and MCF, regardless of the activator used.[38] An increase in fibrinogen concentration causes a hypercoagulable tendency, whereas a decrease leads to a hypocoagulable tendency in ROTEM variables.[42]

Other factors that influence ROTEM results are proteinuria and an increase in azotemia. A recent study identified hypercoagulability by means of TEG in 7 dogs with renal failure and in 11 dogs with severe proteinuria.[43]

In view of these findings, we applied forward stepwise linear regression to determine the influence these factors had on the ROTEM results. Factors such as protein/creatinine ratio, creatinine and platelet count did not differ between the three groups and did not affect the ROTEM variables on comparison among the three groups. However, platelet count did seem to influence ROTEM variables on intragroup comparison, being directly correlated with MCF on the ex-TEM and in-TEM profiles, and inversely correlated with CFT on the in-TEM profile. The ROTEM variables most affected by platelet count and function were CFT, MCF and α angle which, during a decrease in platelet function, could show a hypocoagulable trend. Although thrombocytopathy is reported in dogs with *Leishmania*, this condition was not found in this study.[14,16] These conditions might not have been detected for two reasons. First, ROTEM is not the most sensitive tool to assess platelet function, and second, the inflammatory condition of these dogs could have activated the coagulation process, by tissue factor-mediated thrombin generation, downregulation of physiological anticoagulant mechanisms and inhibition of fibrinolysis.[44] This hemostatic activation might have balanced the effect of a decrease in platelet function, precluding the detection of a hypocoagulable trend.

Hematocrit and fibrinogen concentrations differed across all three groups. However, among group comparison, hematocrit was inversely correlated only with α angle on the ex-TEM profile, whereas fibrinogen concentration was correlated with CFT, MCF and α angle on the in-TEM profile, with all parameters on the ex-TEM profile, and with CT and MCF on the fib-TEM profile. Then, statistically significant differences between groups S versus H and T were due in part to the increase in fibrinogen, minimally to the decrease in hematocrit,: thus, *Leishmania* infection and inflammation may play a role in activating the coagulation system. [36,44]

Comparison between groups H and T showed few statistically significant differences, limited to a decrease in CT on the ex-TEM profile and an increase in MCF and α angle on the fib-TEM profile. Since there was no difference in fibrinogen concentration between groups H and T, the persistence of infection and some degree of inflammation might explain the alterations of ROTEM variables. The present study has several limitations. First, the small number of dogs enrolled limits generalization of the results. Second, we did not investigate of inflammatory proteins and mechanisms of inflammation-induced coagulation and fibrinolysis activation (e.g., protein C, protein S, antithrombin, tissue factor patway inhibitor and plasminogen activator inhibitor type 1). Third, because the study was conducted in a reference hospital, it was not possible to follow up the same symptomatic dogs over the course of their treatment. Such a study design (paired data) could have allowed us to obtain stronger and more generalizable results. Finally, none of the symptomatic dogs in our population presented important organ injury/failure related to leishmaniasis, which might explain the few hemostasis alterations identified.

In conclusion, this study showed normal standard coagulation profiles in all three groups. Comparison of the ROTEM variables showed statistically significant differences between group S versus groups T and H, while remaining within the reference ranges. These differences could have partially due to an increase in fibrinogen concentration and minimally to a decrease in hematocrit. In group T most of the hematological, biochemical and urinalysis parameters returned to within the normal ranges and only a few ROTEM variables differed from those of group H. The ROTEM results did not fall outside of the maximum values of the reference ranges and the clinical relevance of this finding is questionable.

Footnotes

[a] ADVIA 120 Hematology, Siemens Healthcare Diagnostics, Tarrytown, NY, USA.

[b] ILAB 300 plus, Clinical Chemistry System, Instrumentation Laboratories, Milan, Italy.

[c] Multistix 10 SG Reagent Strips, Siemens Healthcare Diagnostics, Tarrytown, NY, USA.

308   ^d Snap 4 Dx, IDEXX Laboratories, Westbrook, ME, USA.

309   ^e Venosafe 3.8% buffered sodium citrated, Terumo, Leuven, Belgium.

310   ^f Coagulometer StART, Diagnostica Stago, New York, USA.

311   ^g ROTEM, Tem International GmbH, Munich, Germany.

312   ^h Star-TEM 10 (0.2 mol/l CaCl2 in HEPES buffer pH 7.4 and 0.1% sodium azide in glass vials),

313   Tem International GmbH, Munich, Germany.

314   ⁱ In-TEM (partial thromboplastin phospholipid made of rabbit brain (chloroform extract), ellagic

315   acid, buffer, preservatives in small glass vials), Tem International GmbH, Munich, Germany.

316   ^l Ex-TEM (recombinant tissue factor and phospholipids, heparin inhibitor, preservatives and buffer

317   in small glass vials), Tem International GmbH, Munich, Germany.

318   ^m Fib-TEM (Cytochalasin D / DMSO solution 0.2 mol/l CaCl2 in HEPES buffer pH 7.4,

319   preservative in glass vials), Tem International GmbH, Munich, Germany.

320   ⁿ Stata Statistical Software: Release 11. StataCorp LP, College Station, TX, USA.

321

References

323   1. Ciaramella P, Oliva G, De Luna R et al. A retrospective clinical study of canine leishmaniasis in

324   150 dogs naturally infected by Leishmania infantum. Vet Rec 1997; 141(21): 539-543.

325   2. Koutinas AF, Polizopoulou ZS, Saridomichelakis MN et al. Clinical considerations on canine

326   visceral leishmaniasis in Greece: a retrospective study of 158 cases (1989-1996). J Am Anim Hosp

327   Assoc 1999; 35(5):376-383.

328   3. Pumarola M, Brevik L, Badiola J et al. Canine leishmaniasis associated with systemic vasculitis

329   in two dogs. J Comp Pathol 1991; 105(3):279-286.

330   4. Ridley DS, Ridley M. The evolution of the lesion in cutaneous leishmaniasis. J Pathol 1983;

331   141(1), 83-96.

332 5. Naranjo C, Fondevila D, Leiva M, Roura X, Peña T. Characterization of lacrimal gland lesions

333 and possible pathogenic mechanisms of keratoconjunctivitis sicca in dogs with leishmaniosis. Vet

334 Parasitol 2005; 133(1):37-47.

335 6. Koutinas AF, Kontos V, Kaldimidrou H, Lekkas S. Canine leishmaniasis-associated

336 nephropathy: a clinical clinicopathologic and pathologic study in 14 spontaneous cases with

337 proteinuria. Europ J Comp Anim Prac 1995; 5:31-38.

338 7. Zatelli A, Borgarelli M, Santilli R et al. Glomerular lesions in dogs infected with Leishmania

339 organisms. Am J Vet Res 2003; 64(5):558-561.

340 8. Font A, Closa JM, Molina A, Mascort J. Thrombisis and nephrotic syndrome in a dog with

341 visceral leishmaniasis. J Small Anim Pract 1993; 34(9), 466-470.

342 9. Font A, Gines C, Closa JM, Mascort J. Visceral leishmaniasis and disseminated intravascular

343 coagulation in a dog. J Am Vet Med Assoc 1994; 204(7):1043-1044.

344 10. Binhazim AA, Chapman WL Jr, Latimer KS, Styles M, Comer K. Canine leishmaniasis caused

345 by Leishmania leishmania infantum in two Labrador retrievers. J Vet Diagn Invest 1992; 4(3):299-

346 305.

347 11. Ciaramella P, Corona M. Canine Leishmaniasis: clinical and diagnostic aspects. Comp Cont

348 Educ Pract Vet 2003; 25, 358-369.

349 12. Moreno P, Lucena R, Ginel PJ et al. Evaluation of primary haemostasis in canine leishmaniasis.

350 Vet Rec. 1998 Jan 24; 142(4):81-83.

351 13. Valladares JE, Ruiz De Gopegui R, Riera C et al. Study of haemostatic disorders in

352 experimentally induced leishmaniasis in Beagle dogs. Res Vet Sci 1998; 64(3):195-198.

353 14. Ciaramella P, Pelagalli A, Cortese L et al. Altered platelet aggregation and coagulation

354 disorders related to clinical findings in 30 dogs naturally infected by Leishmania infantum. Vet J

355 2005; 169(3):465-467.

15. Terrazzano G, Cortese L, Piantedosi D et al. Presence of anti-platelet IgM and IgG antibodies in dogs naturally infected by Leishmania infantum. Vet Immunol Immunopathol 2006; 110(3-4):331-337.

16. Cortese L, Sica M, Piantedosi D, Ruggiero G. et al. Secondary immune-mediated thrombocytopenia in dogs naturally infected by Leishmania infantum. Vet Rec 2009;164(25):778-782.

17. Pelagalli A, Ciaramella P, Lombardi P et al. Evaluation of adenosine 5'-diphosphate (ADP)- and collagen-induced platelet aggregation in canine leishmaniasis. J Comp Pathol 2004; 130(2-3):124-129.

18. Moreno P. Evaluation of secondary haemostasis in canine leishmaniasis. Vet Rec 1999; 144(7):169-171.

19. Cortese L, Pelagalli A, Piantedosi D. et al. The effects of prednisone on haemostasis in leishmaniotic dogs treated with meglumine antimoniate and allopurinol. Vet J 2008; 177(3):405-410.

20. Cortese L, Pelagalli A, Piantedosi D et al. Effects of therapy on haemostasis in dogs infected with Leishmania infantum, Ehrlichia canis, or both combined. Vet Rec 2009; 164(14):433-434.

21. Smith SA. The cell-based model of coagulation. J Vet Emerg Crit Care (San Antonio) 2009;19(1):3-10.

22. Otto CM, Rieser TM, Brooks MB, Russell MW. Evidence of hypercoagulability in dogs with parvoviral enteritis. J Am Vet Med Assoc 2000; 217(10):1500-1504.

23. Donahue SM, Otto CM. Thromboelastography: a tool for measuring hypercoagulability, hypocoagulability and fibrinolysis. J Vet Emerg Crit Care 2005; 15(1): 9-16.

24. Kristensen AT, Wiinberg B, Jessen LR, Andreasen E, Jensen AL. Evaluation of human recombinant tissue factor-activated thromboelastography in 49 dogs with neoplasia. J Vet Intern Med 2008; 22(1):140-147.

381   25. Wiinberg B, Jensen AL, Johansson PI et al. Thromboelastographic evaluation of hemostatic

382   function in dogs with disseminated intravascular coagulation. J Vet Intern Med 2008; 22(2):357-

383   365.

384   26. Wagg CR, Boysen SR, Bédard C et al. Thrombelastography in dogs admitted to an intensive

385   care unit. Vet Clin Pathol 2009; 38(4):453-461.

386   27. Kol A, Borjesson DL. Application of thrombelastography/thromboelastometry to veterinary

387   medicine. Vet Clin Pathol 2010; 39(4):405-416.

388   28. McMichael MA, Smith SA. Viscoelastic coagulation testing: technology, applications, and

389   limitations. Vet Clin Pathol 2011; 40(2):140-153.

390   29. Paltrinieri S, Solano-Gallego L, Fondati A et al.; Canine Leishmaniasis Working Group, Italian

391   Society of Veterinarians of Companion Animals. Guidelines for diagnosis and clinical classification

392   of leishmaniasis in dogs. J Am Vet Med Assoc 2010; 236(11):1184-1191.

393   30. Oliva G, Roura X, Crotti A et al. Guidelines for treatment of leishmaniasis in dogs. J Am Vet

394   Med Assoc 2010; 236(11):1192-1198.

395   31. Altman DG. Practical statistics for medical research. Ed. Chapman & Hall Chapman & Hall;

396   1991, p. 214.

397   32. Liew FY, O'Donell CA. Immunology of leishmaniasis. Adv Parasitol 1993; 32:161–259.

398   33. Pinelli E, Killick-Kendrick R, Wagenaar J.et al. Cellular and humoral immune responses in

399   dogs experimentally and naturally infected with Leishmania infantum. Infect Immun 1994;

400   62(1):229-235.

401   34. Costa CH, Werneck GL, Costa DL. et al. Is severe visceral leishmaniasis a systemic

402   inflammatory response syndrome? A case control study. Rev Soc Bras Med Trop 2010; 43(4):386-

403   392.

404   35. Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, endothelium, and

405   coagulation in sepsis. J Leukoc Biol. 2008; 83(3):536-545.

406   36. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N

407   Engl J Med 1999; 340(6):448-54.

408   37. Martínez-Subiela S, Bernal LJ, Cerón JJ. Serum concentrations of acute-phase proteins in dogs

409   with leishmaniosis during short-term treatment. Am J Vet Res 2003; 64(8):1021-1026.

410   38. Smith SA, McMichael MA, Gilor S, Galligan AJ, Hoh CM. Correlation of hematocrit, platelet

411   concentration, and plasma coagulation factors with results of thromboelastometry in canine whole

412   blood samples. Am J Vet Res 2012;73(6):789-798.

413   39. Smith SA, McMichael MA, Galligan AJ, Swanson K, Morrissey JH. Effect of in vivo reduction

414   in red blood cells mass on results on canine whole blood thromboelastometry (abstract). J Thromb

415   Hemost 2009;7:PP-TH-255.

416   40. Wiinberg B, Jensen AL, Rozanski E. et al. Tissue factor activated thromboelastography

417   correlates to clinical signs of bleeding in dogs. Vet J 2009;179(1):121-129.

418   41. Liebenberg C, Goddard A, Wiinberg B. et al. Hemostatic abnormalities in uncomplicated

419   babesiosis (Babesia rossi) in dogs. J Vet Intern Med; 27(1):150-156.

420   42. Nielsen VG, Cohen BM, Cohen E. Effects of coagulation factor deficiency on plasma

421   coagulation kinetics determined via thrombelastography: critical roles of fibrinogen and factors II,

422   VII, X and XII. Acta Anaesthesiol Scand 2005;49(2):222-231.

423   43. Donahue SM, Brooks M, Otto CM. Examination of hemostatic parameters to detect

424   hypercoagulability in dogs with severe protein-losing nephropathy. J Vet Emerg Crit Care (San

425   Antonio) 2011;21(4):346-355.

426   44. Levi M, Keller TT, van Gorp E, ten Cate H. Infection and inflammation and the coagulation

427   system. Cardiovasc Res 2003; 60(1):26-39.

428   45. Falco S, Bruno B, Maurella C. et al. In vitro evaluation of canine hemostasis following dilution

429   with hydroxyethyl starch (130/0.4) via thromboelastometry. J Vet Emerg Crit Care (San Antonio)

430   2012;22(6):640-645.

431

432 **Table 1**: Guidelines for diagnosis and clinical classification of leishmaniasis in dogs.[29,30]

Stage of leishmaniasis	Features
A: Exposed	Includes dogs with negative cytologic, histologic, parasitological and molecular findings and low antibody titers against *Leishmania*. Dogs are clinically normal or have signs associated with other diseases.
B: Infected	Includes dogs in which parasites have been detected through direct diagnostic methods (eg. microscopic evauation, organism culture, or PCR assay) and with low antibody titers against *Leishmania*. Dogs are clinically normal or have signs associated with other diseases.
C: Sick (clinically evident disease)	Includes dogs with positive cytologic results regardless of serologic results, dogs with high antibody titers against Leishmania spp, and rarely infected dogs. One or more clinical signs common to leishmaniasis are present. Given the varied clinical manifestations of the disease, observed signs suggestive of disease can differ from the common clinical signs, as long as they can be clearly associated with ongoing infection. When physical examination does not reveal clinical signs, dogs in this category should still be defined as sick when hematologic, biochemical and urinary alterations common to leishmaniasis are detected. Laboratory changes other than those considered common can also be indicative of disease, provided that they are associated with the infection.

433

434

435

436

437

438

439

440

441

442

443 **Table 2**: Current treatment protocols for canine leishmaniosis recommended by the Canine
444   Leishmaniasis Working Group.[30]
445

Drugs	Dosages
Meglumine antimoniate	100 mg/Kg SC, once a day for 4 weeks or 50 mg/Kg SC, twice a day for 4-8 weeks
Allopurinol	10 mg/Kg PO, twice a day for 6-12 months
Miltefosine	2 mg/Kg OS, once a day for 28 days
Allopurinol	10 mg/Kg PO, twice a day for 6-12 months

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

Table 3:Institutional reference intervals for ROTEM tests obtained in a group of 45 healthy dogs. [45]

Test	CT s	CFT s	MCF mm	α °
in-TEM	126– 363	47-224	50-75	55-81
ex-TEM	29-92	54-275	36-73	47-79
fib-TEM	14-102	na*	6-26	40-78

* not applicable;

Values are expressed as 5th-95th percentile (95% confidence intervals).

CT, clotting time; CFT, clot formation time; MCF, maximum clot firmness; alpha, angle α

Table 4: Hematocrit and fibrinogen concentrations in groups S, T and H.

Variable	Group S	Group T	Group H
Hematocrit L/L	0.33 (0.2-0.42) [32.9% (20-42)] *P=0.001 # P=0.001	0.43 (0.32-0.56) [43.3% (31.6-56.4)] £ P=0.16	0.45 (0.38-0.56) [44.8% (37.6-56)]
Fibrinogen µmol/L	12.45 (5.3-32.2) [424 mg/dL (180-1094)] *P=0.002 # P=0.001	8 (0.29-27.2) [273 mg/dL (150-926)] £ P=0.099	6.8 (3.2-14.2) [230 mg/dL (133-484)]

Data are expressed as median, minimum and maximum.

* statistically significant differences between group S and group H, # statistically significant differences between group S and group T, £ statistically significant differences between group T and group H (P <0.05).

Table 5: Results of forward stepwise linear regression (P<0.05). All variables that differed between the groups were analysed.

Dependent variables	Independent variables	Log estimate	95% Confidence Interval	Standard Error	P value
in-TEM CFT	Fibrinogen	-0.414	-0.624 - -0.205	0.105	**0.01**
	Platelet	-0.356	-0.584 - -0.128	0.114	**0.003**
	Hematocrit	0.021	-0.485 - -0.528	0.254	0.93
in-TEM MCF	Fibrinogen	0.103	0.020 - 0.186	0.041	**0.015**
	Platelet	0.107	0.014 - 0.2	0.046	**0.025**
in-TEM α	Fibrinogen	0.107	0.047 – 0.168	0.030	**0.001**
	Platelet	-0.051	-0.195 - -0.092	0.072	0.475
	Hematocrit	0.056	-0.008 - -0.121	0.032	0.09
ex-TEM CT	Fibrinogen	-0.166	-0.324 - -0.009	0.079	**0.038**
	Hematocrit	0.279	-0.113 - -0.672	0.197	0.161
ex-TEM CFT	Fibrinogen	-0.518	-0.713 - -0.323	0.097	**0.001**
	Hematocrit	0.191	-0.310 - -0.693	0.252	0.449
ex-TEM MCF	Fibrinogen	0.113	0.028 - 0.198	0.042	**0.01**
	Platelet	0.103	0.008 - 0.199	0.047	**0.033**
ex-TEM α	Fibrinogen	0.147	0.100 - 0.193	0.023	**0.001**
	Hematocrit	-0.168	-0.283 - -0.053	0.057	**0.005**
fib-TEM CT	Fibrinogen	-0.211	-0.391 - -0.031	0.903	**0.022**
	Hematocrit	-0.224	-0.661 - -0.212	0.219	0.31
fib-TEM MCF	Fibrinogen	0.642	0.489 - 0.795	0.076	**0.001**
	Platelet	0.168	-0.676 - 0.083	0.190	0.124
	Hematocrit	-0.296	-0.006 - -0.342	0.087	0.059
	UPC	0.03	-0.018 - 0.078	0.024	0.22
fib-TEM α	Fibrinogen	0.177	-0.031 - 0.385	0.104	0.09
	Platelet	0.191	-0.049 - 0.431	0.120	0.118

CT, clotting time (sec); CFT, clot formation time (sec); MCF, maximum clot firmness (mm);

ALPHA, angle α (degree); UPC, protein/creatinine ratio

522   Figure legends

523   **Figure 1**: Example of a normal thromboelastogram (ex-TEM profile).

524   CT clotting time, CFT clot formation time, MCF maximum clot firmness.

525   **Figure 2**: Pie chart of breed distribution in group S (symptomatic dogs before treatment).

526   Others breed: Great Dane, Pug, Dobermann, Galgo, Siberian husky, and English Mastiff.

527   **Figure 3**: Pie chart of breed distribution in group T (asymptomatic dogs after treatment).

528   Others breed: Great Dane, Galgo, Labrador retriever and English setter.

529   **Figure 4**: Pie chart of breed distribution in group H (control group).

530   **Figure 5**: Box plots representing the significant differences in the ROTEM parameters between the

531   three groups. Outliers have been excluded (P <0.05).

532   Group S symptomatic dogs before treatment, Group T asymptomatic dogs after treatment, Group H

533   control group. CT clotting time (sec); CFT clot formation time (sec); MCF maximum clot firmness

534   (mm); ALPHA alpha angle (degree).

535   ***** statistically significant differences between group S and group H. In-TEM profile: CFT

536   (P=0.0002); MCF (P=0.0116); α angle (P=0.0001). Ex-TEM profile: CT (P=0.0002); CFT,

537   (P=0.00001); MCF (P=0.0146); α angle (P=0.00001). Fib-TEM profile: MCF (P=0.00001); α

538   angle (P=0.001).

539   **#** statistically significant differences between group S and group T. In-TEM profile: CFT

540   (P=0.0064); MCF (P=0.00352); α angle (P=0.0179). Ex-TEM profile: CFT (P=0.00363); MCF

541   (P=0.0146); α angle (P=0.0074). Fib-TEM profile: MCF (P=0.0009).

542   **£** statistically significant differences between group T and group H. Ex-TEM profile: CT

543   (P=0.0001); Fib-TEM profile: MCF (P=0.00372); α angle (P=0.0259).

544

545

546